Polymyositis and dermatomyositis risk factors: Difference between revisions
Jump to navigation
Jump to search
m Bot: Removing from Primary care |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as infection, malignancy, and drug toxicities from statins or immune checkpoint inhibitors. | Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as [[infection]], [[Cancer|malignancy]], and drug toxicities from [[statins]] or immune checkpoint inhibitors. | ||
==Risk Factors== | ==Risk Factors== | ||
*Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as infection, malignancy, and drug toxicities from statins or immune checkpoint inhibitors.<ref name="pmid29579414">{{cite journal |vauthors=Adler BL, Christopher-Stine L |title=Triggers of inflammatory myopathy: insights into pathogenesis |journal=Discov Med |volume=25 |issue=136 |pages=75–83 |date=February 2018 |pmid=29579414 |doi= |url=}}</ref> | *Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as [[infection]], [[Cancer|malignancy]], and drug toxicities from [[statins]] or immune checkpoint inhibitors.<ref name="pmid29579414">{{cite journal |vauthors=Adler BL, Christopher-Stine L |title=Triggers of inflammatory myopathy: insights into pathogenesis |journal=Discov Med |volume=25 |issue=136 |pages=75–83 |date=February 2018 |pmid=29579414 |doi= |url=}}</ref><ref name="DoblougGaren2015">{{cite journal|last1=Dobloug|first1=Cecilie|last2=Garen|first2=Torhild|last3=Bitter|first3=Helle|last4=Stjärne|first4=Johan|last5=Stenseth|first5=Guri|last6=Grøvle|first6=Lars|last7=Sem|first7=Marthe|last8=Gran|first8=Jan Tore|last9=Molberg|first9=Øyvind|title=Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort|journal=Annals of the Rheumatic Diseases|volume=74|issue=8|year=2015|pages=1551–1556|issn=0003-4967|doi=10.1136/annrheumdis-2013-205127}}</ref><ref name="ChinoyFertig2007">{{cite journal|last1=Chinoy|first1=H.|last2=Fertig|first2=N.|last3=Oddis|first3=C. V|last4=Ollier|first4=W. E R|last5=Cooper|first5=R. G|title=The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis|journal=Annals of the Rheumatic Diseases|volume=66|issue=10|year=2007|pages=1345–1349|issn=0003-4967|doi=10.1136/ard.2006.068502}}</ref><ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref><ref name="DouglasTazelaar2001">{{cite journal|last1=Douglas|first1=William W.|last2=Tazelaar|first2=Henry D.|last3=Hartman|first3=Thomas E.|last4=Hartman|first4=Robert P.|last5=Decker|first5=Paul A.|last6=Schroeder|first6=Darrell R.|last7=Ryu|first7=Jay H.|title=Polymyositis–Dermatomyositis-associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=164|issue=7|year=2001|pages=1182–1185|issn=1073-449X|doi=10.1164/ajrccm.164.7.2103110}}</ref> | ||
===Common Risk Factors=== | ===Common Risk Factors=== | ||
*Common risk factors in the development of polymyositis and dermatomyositis include: | *Common risk factors in the development of polymyositis and dermatomyositis include:<ref name="pmid29579414" /><ref name="DoblougGaren2015" /><ref name="ChinoyFertig2007" /><ref name="DalakasHohlfeld2003" /><ref name="DouglasTazelaar2001" /> | ||
**Viral infections such as: | **Viral [[Infection|infections]] such as: | ||
*** Coxsackie B virus | *** [[Coxsackie B|Coxsackie B virus]] | ||
*** Parvovirus | *** [[Parvovirus]] | ||
*** Enterovirus | *** [[Enterovirus]] | ||
*** Human T-cell lymphotropic virus (HTLV-1) | *** [[Human T-lymphotropic virus|Human T-cell lymphotropic virus]] ([[Human T-lymphotropic virus|HTLV-1]]) | ||
*** Human immunodeficiency virus (HIV) | *** [[Human Immunodeficiency Virus (HIV)|Human immunodeficiency virus]] ([[Human Immunodeficiency Virus (HIV)|HIV]]) | ||
*** Epstein-Barr virus (EBV) | *** [[Epstein Barr virus|Epstein-Barr virus]] ([[Epstein Barr virus|EBV]]) | ||
*** Adenovirus | *** [[Adenoviridae|Adenovirus]] | ||
*** Influenza | *** [[Influenza]] | ||
**Malignancy such as: | **[[Cancer|Malignancy]] such as: | ||
*** Ovarian | *** [[Ovary|Ovarian]] | ||
*** Lung | *** [[Lung]] | ||
*** Gastric | *** [[Stomach|Gastric]] | ||
*** Colorectal | *** [[Colorectal]] | ||
*** Pancreatic | *** [[Pancreas|Pancreatic]] | ||
*** Non-Hodgkin’s lymphoma | *** [[Non-Hodgkin lymphoma|Non-Hodgkin’s lymphoma]] | ||
** | **[[Medication|Medications]] such as: | ||
***Statins | ***[[Statins]] | ||
***Immune checkpoint inhibitors such as: | ***Immune checkpoint inhibitors such as: | ||
**** Ipilimumab | **** [[Ipilimumab]] | ||
**** Pembrolizumab | **** [[Pembrolizumab]] | ||
**** Interferon-alpha | **** [[Interferon-alpha]] | ||
**** IL-2 therapy | **** [[Interleukin 2|IL-2]] therapy | ||
===Less Common Risk Factors=== | ===Less Common Risk Factors=== | ||
*Less common risk factors in the development of polymyositis and dermatomyositis include: | *Less common risk factors in the development of polymyositis and dermatomyositis include:<ref name="SchiffenbauerFaghihi-Kashani2018">{{cite journal|last1=Schiffenbauer|first1=Adam|last2=Faghihi-Kashani|first2=Sara|last3=O’Hanlon|first3=Terrence P.|last4=Flegel|first4=Willy A.|last5=Adams|first5=Sharon D.|last6=Targoff|first6=Ira N.|last7=Oddis|first7=Chester V.|last8=Ytterberg|first8=Steven R.|last9=Aggarwal|first9=Rohit|last10=Christopher-Stine|first10=Lisa|last11=Shamim|first11=Ejaz A.|last12=Dellaripa|first12=Paul F.|last13=Danoff|first13=Sonye K.|last14=Mammen|first14=Andrew|last15=Miller|first15=Frederick W.|title=The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis|journal=Seminars in Arthritis and Rheumatism|year=2018|issn=00490172|doi=10.1016/j.semarthrit.2018.02.003}}</ref> | ||
** | **[[Tobacco smoking]] (association with [[interstitial lung disease]] and rise in anti-Jo-1 antibody) | ||
**Maternal [[smoking]] during pregnancy (risk factor for a [[juvenile dermatomyositis]]) | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | |||
[[Category:Rheumatology]] | |||
[[Category:Dermatology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 23:47, 29 July 2020
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis risk factors On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis risk factors |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as infection, malignancy, and drug toxicities from statins or immune checkpoint inhibitors.
Risk Factors
- Common risk factors in the development of polymyositis and dermatomyositis include environmental factors such as infection, malignancy, and drug toxicities from statins or immune checkpoint inhibitors.[1][2][3][4][5]
Common Risk Factors
- Common risk factors in the development of polymyositis and dermatomyositis include:[1][2][3][4][5]
- Viral infections such as:
- Malignancy such as:
- Medications such as:
- Statins
- Immune checkpoint inhibitors such as:
- Ipilimumab
- Pembrolizumab
- Interferon-alpha
- IL-2 therapy
Less Common Risk Factors
- Less common risk factors in the development of polymyositis and dermatomyositis include:[6]
- Tobacco smoking (association with interstitial lung disease and rise in anti-Jo-1 antibody)
- Maternal smoking during pregnancy (risk factor for a juvenile dermatomyositis)
References
- ↑ 1.0 1.1 Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
- ↑ 2.0 2.1 Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
- ↑ 3.0 3.1 Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
- ↑ 4.0 4.1 Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ 5.0 5.1 Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
- ↑ Schiffenbauer, Adam; Faghihi-Kashani, Sara; O’Hanlon, Terrence P.; Flegel, Willy A.; Adams, Sharon D.; Targoff, Ira N.; Oddis, Chester V.; Ytterberg, Steven R.; Aggarwal, Rohit; Christopher-Stine, Lisa; Shamim, Ejaz A.; Dellaripa, Paul F.; Danoff, Sonye K.; Mammen, Andrew; Miller, Frederick W. (2018). "The impact of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis". Seminars in Arthritis and Rheumatism. doi:10.1016/j.semarthrit.2018.02.003. ISSN 0049-0172.